ArticleMedical oncology (Northwood, London, England)2014
Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Comparison of HIF-1α and survivin levels in patients with diabetes and retinopathy of varying severity.Arquivos brasileiros de oftalmologia · 2024Article
- Review
- Role of hypoxia-inducible factor-1α and survivin in oxygen-induced retinopathy in mice.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the expression of PIK3CA and survivin in adenosquamous lung cancer (ASC) patients and their clinicopathological significance. A total of 32 patients with adenosquamous carcinoma and ten cases of normal lung lesion were investigated, and the expressions of PIK3CA and survivin were detected by immunohistochemistry. The PIK3CA and survivin expression in adenosquamous lung carcinoma tissues was significantly higher than those of the normal lesions (p = 0.02). The positive rate of PIK3CA and survivin expressions was in accordance with the tumor-node-metastasis stage (p = 0.002/0.013), pathological grade (p = 0.019/0.013), and lymph node metastasis (p = 0.029/0.008). Out of 15 patients with definite follow-ups, highly positive expressions of PIK3CA (12 cases) and survivin (11 cases) were suggested to be associated with adverse prognosis (nine cases recurrence and four cases died). A positive correlation was also observed between the expressions of PIK3CA and survivin (r = 0.622, p < 0.001). These findings indicated that PIK3CA and survivin up-regulation might play an important role in lymph node metastasis and adverse prognosis in ASC. Nevertheless, further additional prospective studies in the area of ASC molecular profiling are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.